Consensus Sangamo Therapeutics

Consensus Sangamo Therapeutics, Inc. - SGMO - MarketScreener

Sangamo Therapeutics, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: SGMO | Nasdaq.

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue ...

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per ...

Sangamo reports Q3 EPS 4c, consensus (3c) - TipRanks.com

... Sangamo Therapeutics. “Alongside Pfizer's Hemophilia A program activities, and against a backdrop of our recent epigenetic regulation and ...

Sangamo Therapeutics, Inc.: Target Price Consensus and Analysts ...

Sangamo Therapeutics, Inc. analysts consensus, targets, ratings and recommendations | Berne S.E.: SGMO | Berne S.E..

Sangamo Therapeutics (NASDAQ:SGMO) Stock, Analyst Ratings ...

Sangamo Therapeutics Inc has a consensus price target of $5.36 based on the ratings of 8 analysts. The high is $10 issued by HC Wainwright & Co. on November ...

Sangamo (SGMO) Stock Forecast & Price Target - Investing.com

Sangamo Therapeutics Inc (SGMO). NASDAQ. Currency in USD. Add to Watchlist ... Overall Consensus. Buy. Created with Highcharts 11.4.8 5 Ratings. 4 Buy.

RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)

Sangamo Therapeutics, Inc. engages in researching and developing ... Sangamo reports Q3 EPS 4c, consensus (3c) · Sangamo options imply ...

SGMO - Sangamo Therapeutics - Earnings Whispers

The company missed consensus estimates by 6.25% while revenue fell 94.79% compared to the same quarter a year ago. Sangamo BioSciences Inc is a clinical stage ...

Sangamo Therapeutics (SGMO) Stock Forecast and Price Target 2024

Based on 3 Wall Street analysts who have issued ratings for Sangamo Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy.

Sangamo Therapeutics Inc. Analyst Estimates - SGMO - MarketWatch

Sangamo Therapeutics Inc. analyst estimates, including SGMO earnings per ... 0. Consensus, N/A, N/A, Overweight. Upgrades/Downgrades. Date, Category, Analyst ...

Long Term Growth % High Consensus For Sangamo Therapeutics ...

How does Sangamo Therapeutics's Long Term Growth % High Consensus benchmark against competitors? We've identified the following companies as similar to Sangamo ...

Sangamo Therapeutics's Earnings Outlook - Benzinga

The consensus rating for Sangamo Therapeutics is Buy, based on 4 analyst ratings. With an average one-year price target of $6.25, there's a ...

Sangamo Therapeutics, Inc. Common Stock (SGMO) Analyst ...

Analyst Price Targets. Consensus. $6. Based on analysts offering 12 month price targets for SGMO in the last 3 months. The average price ...

SGMO: Sangamo Therapeutics - Price & Consenus Chart - Zacks.com

SGMO: Sangamo Therapeutics - Price and Consensus Chart. Get the latest Price and Consensus Chart for Sangamo Therapeutics from Zacks Investment Research.

Sangamo Therapeutics | SGMO Stock Price, Company Overview ...

Cash and Debt Metrics · Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months. · EPS and Revenue estimates are for the ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And ...

With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply ...

Here's Why Analysts Just Lifted Their Sangamo Therapeutics, Inc ...

The consensus price target rose 20% to US$3.80, with the analysts increasingly optimistic about shrinking losses, despite the expected decline in revenue.

Sangamo Therapeutics Inc. Stock Quote (U.S. - SGMO - MarketWatch

SGMO | Complete Sangamo Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Sangamo Therapeutics (NasdaqCM:SGMO) Stock Forecast ...

Future criteria checks 2/6 · Key information · Recent future growth updates · Consensus revenue estimates increase by 32% · Consensus EPS estimates fall by 10%.

Amgen (AMGN), Sangamo Biosciences (SGMO) and Disc Medicine ...

Sponsored ADR, Kiniksa Pharmaceuticals, and Zenas BioPharma, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus ...